GlobalRPH - Arthritis News

Medical News

< back to feeds
Arthritis News (Page 9)
International Researchers Call On Rheumatologists To Help Their Patients Stay Fit For Work Researchers, doctors and patient groups will today call on rheumatologists and related healthcare professionals to view their patients as productive workers and make their staying in work an important outcome in managing their condition. Musculoskeletal Disorders (MSDs) in Europe account for 50% of all work-related disorders and 60% of permanent work incapacity in the EU. ...more	14 June 2009
Wyeth Presents New Analyses Of Data From Three Studies Of ENBREL(R) At The European League Against Rheumatism (EULAR) Annual Meeting Analyses of data from three studies provide insight into the use of ENBREL®(etanercept) in the treatment of three conditions for which ENBREL is indicated: moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). These analyses, presented this week during the European League Against Rheumatism (EULAR) Annual Meeting in Copenhagen, add to the body of evidence that supports treatment with ENBREL for patients with these conditions. ...more	14 June 2009
The Beneficial Effects Of Pregnancy And Childbearing On Arthritic Conditions May Be More Long-Term Than Previously Understood Nulliparous women (those who have not given birth to children) are diagnosed with chronic arthritides (including ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis (RA) an average of 5.2 years before parous women (those who have given birth to children), according to a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. ...more	13 June 2009
New Treatment Strategy Offers Hope To RA Patients Who Failed All Other Therapies Rheumatoid arthritis (RA) patients who failed to respond to initial treatment with rituximab (RTX) (a chimeric monoclonal antibody against the protein CD20) can still be successfully re-treated with a second course of RTX after six months, according to the results of a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. ...more	13 June 2009
Subclinical Markers Predict Relapse In Juvenile Idiopathic Arthritis Post Methotrexate Withdrawal Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark. ...more	13 June 2009
Exercise Improves Functional And Psycological Ability And Reduces Steroid Need In Rheumatoid Arthritis Undertaking a supervised exercise programme can have beneficial effects on functional status and physical function, reduce the need for daily corticosteroid and anti-inflammatory intake and improve levels of depression and anxiety in people with rheumatoid arthritis (RA), according to a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. ...more	13 June 2009
Medivation Completes Enrollment In Confirmatory, Pivotal Phase 3 'CONNECTION' Trial Of Dimebon In Patients With Alzheimer's Disease Medivation, Inc. (Nasdaq: MDVN) announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's disease. The international, double-blind, placebo-controlled, pivotal Phase 3 study enrolled 598 patients, exceeding the enrollment target of 525 patients. More than 40 percent of the patients enrolled were in the United States. ...more	12 June 2009
1/4 Of Patients On Highest Investigational Doses Of CP-690,550 Achieve ACR70 At Week 12 A quarter of active rheumatoid arthritis (RA) patients receiving either 10mg (24.6%) or 15mg (28.1%) twice daily of the investigational oral JAK-3 (janus-associated kinase) inhibitor CP-690,550 (CP) achieved ACR70* after 12 weeks, according to the results of a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. The primary outcome for the study was ACR20*, with 75. ...more	12 June 2009
New Data Showed Cimzia(R) Provided Rapid And Sustained Clinical Response, And Reinforces Need For Rapid-acting Treatments For RA UCB today announced data that showed rapid and sustained improvements in symptoms of RA, as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with certolizumab pegol, together with methotrexate (MTX), was sustained for two years. The results from an open-label extension study*** to RAPID 1*, were presented at the European League Against Rheumatism (EULAR) meeting in Copenhagen. ...more	12 June 2009
Shedding Light On Age Effects In Arthritis Older mice are more susceptible to proteoglycan-induced arthritis (PGIA). Researchers writing in BioMed Central's open access journal Immunity & Ageing have shown, for the first time, that young mice are completely resistant, but become fully susceptible to the disease with age. Tibor Glant, from Rush University Medical Center, Chicago, worked with a team of researchers to investigate the effects of immunological senescence on susceptibility to arthritis. ...more	12 June 2009
MabThera To Reduce The Progression Of Joint Damage When Used As A First-line Biologic Treatment In RA New data show for the first time that a course of 2 infusions of MabThera 1000mg (rituximab, known as Rituxan within the United States) given every 24 weeks as the patient's first biologic can significantly slow down joint damage following 1 year of treatment, with virtually no progression of joint damage seen from six months1. ...more	12 June 2009
New Lupus Drug Showed Positive Results In Trial Said Manufacturer A phase 2 trial of the drug belimumab in patients with active systemic lupus erythematosus (SLE) showed positive results, according to the drug company. ...more	12 June 2009
Tocilizumab Blunts Joint Damage Worsening In Rheumatoid Arthritis Patients COPENHAGEN - The interleukin (IL)-6 receptor inhibitor tocilizumab (ActemraR) combined with methotrexate is more effective than methotrexate monotherapy in inhibiting the progression of structural joint damage in rheumatoid arthritis patients, according to results released at the 10th Annual Congress of the European League Against Rheumatism (EULAR) 2009. ...more	11 June 2009
Early Detection Of Osteoarthritis In Dogs Could Open Doors For A Cure Osteoarthritis is commonly diagnosed in the late and irreversible stages, when treatment can only be expected to decrease pain and slow progression of disease. Because osteoarthritis is a widespread problem in dogs, horses and humans, doctors and veterinarians need a precise way to diagnose the disease early and accurately. ...more	11 June 2009
Genetic Pathway Responsible For Link Between Body Clock Disturbance And Worsening Arthritis The genes that regulate human circadian rhythm, or 'the body clock', are significantly disturbed in individuals with arthritis, according to the results of a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. Notably, a specific genetic pathway has been identified as responsible for interactions between the genes that regulate the body clock and those that may worsen symptoms of arthritis. ...more	11 June 2009
New Risk Factor Gene For Rheumatoid Arthritis Identified By Researchers Scientists at The Feinstein Institute for Medical Research and a team of collaborators from across the country have identified a new risk factor gene for rheumatoid arthritis. The paper will be published in Nature Genetics and the finding brings light to the nature of the disease. The gene, dubbed REL, is a member of the NF-ÎºB family, important transcription factors that have many roles in the body. ...more	11 June 2009
Association Between Rheumatoid Arthritis And Poor Sleep In Women According to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, symptoms of Rheumatoid Arthritis (RA) negatively affect women's sleep. Sleep is further impaired by pain, depression and poor adherence to RA medications. ...more	10 June 2009
Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin(R) From The EMEA Paediatric Committee Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation plan (PIP) for Rhucin® (recombinant human C1 inhibitor) in the therapeutic area of immunology-rheumatology transplantation. ...more	10 June 2009
New Analysis Shows Efficacy Of SIMPONI(TM) (golimumab) In Anti-TNF Experienced Rheumatoid Arthritis Patients A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements in signs and symptoms through week 24, compared with patients receiving placebo. ...more	10 June 2009
Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression Of Structural Joint Damage In Rheumatoid Arthritis Patients One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, experienced a significant inhibition in the progression of structural joint damage compared with patients treated with methotrexate alone. ...more	10 June 2009
Pages of Results: [First Page] [Prev] 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 [Next] [Last Page]
Arthritis News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.